Literature DB >> 6148119

Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study.

W Greil, H Haag, G Rossnagl, E Rüther.   

Abstract

In a double-blind, placebo-controlled study, ten chronic schizophrenic patients with pronounced symptoms of tardive dyskinesia (TD) were withdrawn from anticholinergic medication. All patients had previously been under long-term treatment with neuroleptics and anticholinergics for at least two years. The rating-scales used were the AIMS, our own TD Scale, and the Simpson-Angus scale for extra-pyramidal side-effects. The severity of TD decreased significantly in nine patients with in two weeks; this improvement, most pronounced in the oral region (P less than .001), persisted during a six-week placebo period. There was a slight increase in parkinsonian symptoms (P less than .05), which was not a prerequisite for improvement in TD. Hence, discontinuation of anticholinergic medication is a possible therapeutic approach in patients with TD.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148119     DOI: 10.1192/bjp.145.3.304

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

Review 1.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

2.  Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity.

Authors:  F M Nilsson; B L Hansen; C Buchel; W F Gattaz; J Gerlach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

3.  Treatment Recommendations for Tardive Dyskinesia.

Authors:  Lucia Ricciardi; Tamara Pringsheim; Thomas R E Barnes; Davide Martino; David Gardner; Gary Remington; Donald Addington; Francesca Morgante; Norman Poole; Alan Carson; Mark Edwards
Journal:  Can J Psychiatry       Date:  2019-02-21       Impact factor: 4.356

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 5.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

6.  Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Authors:  Tanuja Bordia; Danhui Zhang; Xiomara A Perez; Maryka Quik
Journal:  Exp Neurol       Date:  2016-09-19       Impact factor: 5.330

7.  Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.

Authors:  Tamara Pringsheim; Asif Doja; Stacey Belanger; Scott Patten
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

8.  [Not Available].

Authors:  Tamara Pringsheim; Asif Doja; Stacey Belanger; Scott Patten
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

Review 9.  Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

10.  A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia.

Authors:  Sahel Hemmati; Ali Nazeri Astaneh; Farin Solemani; Roshanak Vameghi; Firouzeh Sajedi; Naser Tabibi
Journal:  Iran J Psychiatry       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.